Floatz logo

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)

Burkholderia Cepacia Infection

Synspira, Inc.OtherPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Burkholderia Cepacia Infection cohort.

Asset / SponsorPhaseRating
Tazobactam
Sunshine Coast Hospital and Health Service
Phase 4BB
CEFTOLOZANE
Sunshine Coast Hospital and Health Service
Phase 4BB

Same molecule, other indications

POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW) is also rated in:

pneumonitisDormant
CC
Indicative ·
43 / 100
View asset →
burkholderia infectious diseaseDormant
CC
Indicative ·
43 / 100
View asset →
respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →